VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced that Chief Scientific Officer Iain Stuart, Ph.D., will present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference on July 27, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced that Chief Scientific Officer Iain Stuart, Ph.D., will present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference on July 27, 2022. The presentation, titled The InhiBET™ Platform: Bromodomain and End Terminal (BET) Inhibitors in Autoimmune Disease, will focus on harnessing autoantibody signatures. VYNE is developing innovative therapies for immuno-inflammatory conditions, including its proprietary treatments like FMX114 for atopic dermatitis and a library of BET domain inhibitors.
Details
News Market Reaction – VYNE
The recorded move for VYNE in the trading session of this news was -0.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Iain Stuart, Ph.D., Chief Scientific Officer of VYNE, will be presenting at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) on July 27, 2022.
| B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) – Presentation Details | |
| Presentation Date: | July 27, 2022 |
| Presenter: | Iain Stuart, Ph.D., Chief Scientific Officer of VYNE |
| Presentation Track: | Harnessing Autoantibody Signatures and Mapping Out the B&T Cell-Mediated Autoimmune Disease Landscape |
| Presentation Title: | The InhiBET™ Platform: Bromodomain and End Terminal (BET) Inhibitors in Autoimmune Disease |
Slides will be accessible on the “Events and Presentation” section of the VYNE website at https://vynetherapeutics.com/investors-media/events_presentations/
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis, and access to a library of bromodomain & extra-terminal (BET) domain inhibitors licensed from In4Derm Limited. The BET inhibitor platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi) and access to a library of (BET) domain inhibitors for the potential treatment of immuno-inflammatory conditions.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.